Tag: PSMA
FDA Grants Fast Track Designation for ARX517 in Metastatic Castration-Resistant Prostate...
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARX517, a proprietary anti-PSMA antibody-drug conjugate (ADC) investigational being therapy developed by Ambrx for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) upon progression on an androgen receptor pathway inhibitor.
Progenics and Selexis Sign Commercial License Agreement for Use of Proprietary...
Privately held biotechnology company Selexis, a pioneering life sciences company and a global leader in mammalian, suspension-adapted CHO-K1, cell line generation, has entered in...
